Patients deserve a plan made just for them.
We’ve done just that.
OncologyReasoning puts tumor-board reasoning in the palm of your hand. It reasons over a patient’s entire longitudinal record — every prior line, the genomics, the labs, the full course — and builds a patient-specific treatment plan in minutes. No AI, no black box: it’s deterministic, and every claim traces to its source.
Why this: on confirmed multifocal progression, the acquired BRAF V600E reactivates MAPK downstream of EGFR — a recognized bypass after TKI progression, and T790M is absent. The mechanism-matched move keeps EGFR control on osimertinib and adds BRAF/MEK (dabrafenib + trametinib). The model flags this as emerging, off-label evidence — so it surfaces clinical-trial evaluation alongside and names docetaxel + ramucirumab as the SOC-bridge fallback. TP53 co-mutation noted.
From records to reasoning in minutes
No forms, no structured data entry. The engine reads the patient’s records the way they were written — and reasons through every case the same rigorous way, every time.
Upload the chart
Drop in the patient’s real records — pathology, molecular panels, labs, prior treatments, imaging and notes. No forms, no data entry. The engine reads the chart the way it was written.
Records reassembly
Outside scans, prior-line notes, molecular reports from different labs, records faxed in from another institution — fragmented, duplicated, out of order. The engine reconciles them into one clean, chronological case. No more piecing the chart together by hand.
It reads the whole case
From that single source of truth, it works out what’s driving the cancer, how it’s slipping past prior therapy, and the secondary mutations that change the plan. Nothing on the chart gets missed.
It pinpoints where the patient stands
Newly diagnosed, responding, progressing, resistant, post-surgery — the engine places the patient in the exact situation and narrows to the options that genuinely apply, for every driver and the driver-negative paths alike.
A plan you can take to the board
Out comes a clear recommendation — the preferred move, the alternatives, and the reasoning in plain terms — with matching trials and a source behind every call. Tumor-board-ready, traceable end to end.
Every case state covered, with patient-specific reasoning for each
The outer states plus clinical substates span the full picture. Driver-positive cases route into one of 121 terminal buckets; driver-negative cases route through chemo-immunotherapy pathways stratified by histology and PD-L1.
On active therapy with documented response. Monitoring and toxicity management are the clinical priority.
Active therapy with stable or indeterminate response. Structured monitoring protocol in effect.
Confirmed progression on a prior line. A targeted next-line option is available from resistance profiling.
Confirmed progression with no standard targeted option. Trial enrollment is the primary pathway.
Isolated site(s) of progression while systemic disease stays controlled. Local ablation may extend systemic therapy.
No prior systemic therapy. First-line selection based on driver, PD-L1 expression, and disease burden.
Post-curative-resection on adjuvant therapy — a distinct logic tree from metastatic monitoring.
Neoadjuvant, perioperative, and unresectable stage III consolidation tracks modeled on their own logic.
Modeled beneath the outer states
- Neoadjuvant / perioperative active treatment
- Unresectable stage III / consolidation
- Post-curative recurrence
- No actionable driver / IO–chemo pathway
- Best supportive care / treatment-ineligible
Each driver carries its own buckets — 1L, resistance, bypass amplification, transformation, stage III, and adjuvant. Driver-negative cases route through a parallel chemo-immunotherapy lane stratified by histology and PD-L1.
IO–chemo lane
The standard oncology evidence base, woven into one reasoning trail
Recommendations cite the source for every claim — guidelines, regulatory labels, pivotal trials, and literature — so the rationale is auditable from input to output.
driver EGFR Ex19delbypass BRAF V600E (acquired)mechanism bypass pathway activationroute EGFR → BRAF/MEK bypass-targeting
cited: → FDA label · combination indication → NCCN NSCLC · acquired resistance → pivotal trial · PFS / ORR → 17 matched trials · screened to chart
verify against current guidelines →
This should compress work, not add it
We're early — no clinician testimonials yet. But the engine is built around four concrete moments in the workflow, and the value compounds at each one.
Thinking, already done
Engine output ready before the patient walks in: structured summary, options, and trial matches already organized. The 20-minute slot starts with the work behind you.
Prep replacementNothing missed
Post-progression. Atypical drivers. Resistance configurations. Co-mutation contexts that change sequencing — checked across every major NSCLC driver, every resistance pathway, every case state.
Safety net & sanity checkThe right one, in context
Trial relevance surfaced inside the treatment decision, not as a separate research task — the right trial, at the right moment, screened against the chart.
Surfacing, not searchingApproved, not just recommended
The same recommendation generates the prior-authorization, reauthorization, or medical-necessity letter — diagnosis, codes, prior lines, and the supporting evidence already in place. Deterministic and never fabricated; the physician reviews, signs, and submits.
Recommendation to reimbursementReady to see it on your cases?
Request access and we'll onboard your institution within 48 hours. No integration required — just your clinical records.
HIPAA-ready · No PHI stored · For clinical decision support only